サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1538529

ペプチド・オリゴヌクレオチドCDMO市場レポート：2030年までの動向、予測、競合分析

Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ペプチド・オリゴヌクレオチドCDMO市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年07月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ペプチド・オリゴヌクレオチドCDMOの動向と予測

世界のペプチド・オリゴヌクレオチドCDMO市場は、2024年から2030年までのCAGRが11.3%で、2030年までに推定50億米ドルに達すると予想されます。この市場の主な促進要因は、カスタマイズ医療の人気の高まり、希少疾患への関心の高まり、ペプチド抗ウイルス薬への重点の高まりです。世界のペプチド・オリゴヌクレオチドCDMO市場の将来は、製薬企業とバイオ医薬品企業市場に機会があり、有望視されています。

セグメント別ペプチド・オリゴヌクレオチドCDMO

この調査には、世界のペプチド・オリゴヌクレオチドCDMOの製品別、サービスタイプ別、最終用途別、地域別の予測が含まれています。

ペプチド・オリゴヌクレオチドCDMO市場の洞察

Lucintel社は、ペプチドは予測期間中、より大きなセグメントであり続けると予測しています。

同市場では、予測期間中、バイオ医薬品企業がより大きなセグメントであり続けると思われます。

北米は予測期間中最大の地域であることに変わりはないでしょう。

よくある質問

Q1.市場規模は：

A1.世界のペプチド・オリゴヌクレオチドCDMO市場は、2030年までに推定50億米ドルに達すると予想されています。

Q2.市場の成長予測は：

A2.世界のペプチド・オリゴヌクレオチドCDMO市場は、2024年から2030年にかけて11.3%のCAGRで成長すると予測されます。

Q3.市場の成長に影響を与える主な促進要因は：

A3.この市場の主な促進要因は、カスタマイズ医療の人気の高まり、希少疾患への関心の高まり、ペプチド抗ウイルス薬への重点の高まりです。

Q4.市場の主要セグメントは：

A4.ペプチド・オリゴヌクレオチドCDMO市場の将来は、製薬企業およびバイオ医薬品企業市場における機会により有望です。

Q5.市場の主要企業は：

A5.ペプチド・オリゴヌクレオチドCDMOの主要企業は以下の通り：

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis

Q6.今後、最大となる市場セグメントは：

A6.Lucintelは、ペプチドは予測期間中、より大きなセグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.予測期間中、北米が最大の地域であり続ける。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10％のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のペプチド・オリゴヌクレオチドCDMO市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のペプチド・オリゴヌクレオチドCDMO市場の動向（2018-2023）と予測（2024-2030）
  • 製品別世界のペプチド・オリゴヌクレオチドCDMO市場
    • ペプチド
    • オリゴヌクレオチド
  • サービスタイプ別世界のペプチド・オリゴヌクレオチドCDMO市場
    • 受託開発
    • 受託製造
  • 最終用途別世界のペプチド・オリゴヌクレオチドCDMO市場
    • 製薬企業
    • バイオ医薬品企業
    • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

  • 地域別世界のペプチド・オリゴヌクレオチドCDMO市場
  • 北米のペプチド・オリゴヌクレオチドCDMO市場
  • 欧州のペプチド・オリゴヌクレオチドCDMO市場
  • アジア太平洋ペプチド・オリゴヌクレオチドCDMO市場
  • その他地域ペプチド・オリゴヌクレオチドCDMO市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 業務統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • 製品別世界のペプチド・オリゴヌクレオチドCDMO市場の成長機会
    • サービスタイプ別の世界のペプチド・オリゴヌクレオチドCDMO市場の成長機会
    • 最終用途別世界のペプチド・オリゴヌクレオチドCDMO市場の成長機会
    • 地域別の世界のペプチド・オリゴヌクレオチドCDMO市場の成長機会
  • 世界のペプチド・オリゴヌクレオチドCDMO市場の新たな動向
  • 戦略分析
    • 新製品開発
    • 世界のペプチド・オリゴヌクレオチドCDMO市場の能力拡大
    • 世界のペプチド・オリゴヌクレオチドCDMO市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 主要企業の企業プロファイル

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis
目次

Peptide and Oligonucleotide CDMO Trends and Forecast

The future of the global peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets. The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030 with a CAGR of 11.3% from 2024 to 2030. The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Peptide and Oligonucleotide CDMO by Segment

The study includes a forecast for the global peptide and oligonucleotide CDMO by product, service type, end use, and region.

Peptide and Oligonucleotide CDMO Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Peptides
  • Oligonucleotides

Peptide and Oligonucleotide CDMO Market by Service Type [Shipment Analysis by Value from 2018 to 2030]:

  • Contract Development
  • Contract Manufacturing

Peptide and Oligonucleotide CDMO Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others

Peptide and Oligonucleotide CDMO Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Peptide and Oligonucleotide CDMO Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peptide and oligonucleotide CDMO companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peptide and oligonucleotide CDMO companies profiled in this report include-

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis

Peptide and Oligonucleotide CDMO Market Insights

Lucintel forecasts that peptide will remain larger segment over the forecast period.

Within this market, biopharmaceutical company will remain larger segment over the forecast period.

North America will remain the largest region over the forecast period.

Features of the Global Peptide and Oligonucleotide CDMO Market

Market Size Estimates: Peptide and oligonucleotide CDMO market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Peptide and oligonucleotide CDMO market size by product, service type, end use, and region in terms of value ($B).

Regional Analysis: Peptide and oligonucleotide CDMO market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, service types, end uses, and regions for the peptide and oligonucleotide CDMO market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peptide and oligonucleotide CDMO market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the peptide and oligonucleotide CDMO market size?

Answer: The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030.

Q2. What is the growth forecast for peptide and oligonucleotide CDMO market?

Answer: The global peptide and oligonucleotide CDMO market is expected to grow with a CAGR of 11.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the peptide and oligonucleotide CDMO market?

Answer: The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.

Q4. What are the major segments for peptide and oligonucleotide CDMO market?

Answer: The future of the peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets.

Q5. Who are the key peptide and oligonucleotide CDMO market companies?

Answer: Some of the key peptide and oligonucleotide CDMO companies are as follows:

  • PolyPeptide Group
  • STA Pharmaceutical
  • Bachem
  • Creative Peptides
  • Aurigene Pharmaceutical Services
  • Merck
  • EUROAPI
  • Curia Global
  • CordenPharm
  • Sylentis

Q6. Which peptide and oligonucleotide CDMO market segment will be the largest in future?

Answer: Lucintel forecasts that peptide will remain larger segment over the forecast period.

Q7. In peptide and oligonucleotide CDMO market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the peptide and oligonucleotide CDMO market by product (peptides and oligonucleotides), service type (contract development and contract manufacturing), end use (pharmaceutical companies, biopharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Peptide and Oligonucleotide CDMO Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Peptide and Oligonucleotide CDMO Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Peptide and Oligonucleotide CDMO Market by Product
    • 3.3.1: Peptides
    • 3.3.2: Oligonucleotides
  • 3.4: Global Peptide and Oligonucleotide CDMO Market by Service Type
    • 3.4.1: Contract Development
    • 3.4.2: Contract Manufacturing
  • 3.5: Global Peptide and Oligonucleotide CDMO Market by End Use
    • 3.5.1: Pharmaceutical Companies
    • 3.5.2: Biopharmaceutical Companies
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Peptide and Oligonucleotide CDMO Market by Region
  • 4.2: North American Peptide and Oligonucleotide CDMO Market
    • 4.2.1: North American Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.2.2: North American Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
  • 4.3: European Peptide and Oligonucleotide CDMO Market
    • 4.3.1: European Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.3.2: European Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
  • 4.4: APAC Peptide and Oligonucleotide CDMO Market
    • 4.4.1: APAC Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.4.2: APAC Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others
  • 4.5: ROW Peptide and Oligonucleotide CDMO Market
    • 4.5.1: ROW Peptide and Oligonucleotide CDMO Market by Product: Peptides and Oligonucleotides
    • 4.5.2: ROW Peptide and Oligonucleotide CDMO Market by End Use: Pharmaceutical Companies, Biopharmaceutical Companies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Product
    • 6.1.2: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Service Type
    • 6.1.3: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by End Use
    • 6.1.4: Growth Opportunities for the Global Peptide and Oligonucleotide CDMO Market by Region
  • 6.2: Emerging Trends in the Global Peptide and Oligonucleotide CDMO Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Peptide and Oligonucleotide CDMO Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Peptide and Oligonucleotide CDMO Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: PolyPeptide Group
  • 7.2: STA Pharmaceutical
  • 7.3: Bachem
  • 7.4: Creative Peptides
  • 7.5: Aurigene Pharmaceutical Services
  • 7.6: Merck
  • 7.7: EUROAPI
  • 7.8: Curia Global
  • 7.9: CordenPharm
  • 7.10: Sylentis